SomaLogic's leaders and managers have deep and diverse expertise in all aspects of biotechnology and a shared commitment to success.
Byron Hewett, Chief Executive Officer
Byron Hewett joined SomaLogic in December, 2013 after serving most recently as Chairman and CEO at BioBehavioral Diagnostics, Inc. Mr. Hewett previously served as General Manager, President and CEO at Immunicon Corporation. Prior to joining Immunicon, he served as senior Vice President of Sales and Marketing and general manager, North America, for Qiagen. Prior to joining Qiagen, he served as Vice President of Worldwide Marketing in the laboratory testing segment of Bayer Diagnostics (previously Chiron Diagnostics), responsible for strategy and marketing of Bayer's global immunochemistry, hematology, clinical chemistry, high volume urine chemistry, laboratory automation, and information and consulting businesses. He had previously served as Vice President within the US branch of the laboratory testing segment and nucleic acid diagnostics business and as President of the US commercial operations unit for Chiron Diagnostics Mr. Hewett began his business career with Abbott Laboratories advancing to the position of business unit manager in Abbott Laboratories' therapeutic drug monitoring and transplant diagnostics business. Mr. Hewett holds a B.S. from the McIntire School of Commerce at University of Virginia and a Masters in Management from the J.L. Kellogg Graduate School of Management at Northwestern University.
Dan Muehl, Chief Financial Officer
Dan joined SomaLogic in April 2014 with more than 28 years of financial management experience, including CFO roles at three publicly traded technology growth companies. At Somalogic, he applies his expertise in finance and operations management, strategic partnering, financing, investor relations, compliance, and mergers and acquisitions to accelerate the company’s progress toward commercialization of new products and services and coordinating additional funding for continued growth. Prior to joining Somalogic, Dan was CFO of bio-industrial company OPX Biotechnologies, where he closed $47 million in equity and debt financing; vice president of finance at bio-pharmaceutical company Pharmion (prior to its acquisition by Celgene); CFO at biotechnology company Repligen Corporation; CFO at medical device manufacturer Physiometrix Inc.; and CFO and chief operating officer at Number Nine Visual Technology, a computer graphics design and manufacturing company. Dan began his career in public accounting at Ernst & Young. He earned a B.S. in accounting from the University of Massachusetts – Amherst and received his CPA certificate in 1990.
Stephen A. Williams, M.D., Ph.D., Chief Medical Officer
Steve Williams joined SomaLogic in 2009 as chief medical officer. Steve trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. He joined Pfizer in the U.K. in 1989 in experimental medicine, and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the U.S. in 1993 with Pfizer and worked in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was made vice president in 2006. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase III trials.
Nebojsa Janjic, Ph.D., Chief Science Officer
Nebojsa Janjic has been the chief science officer at SomaLogic, Inc. since January 2009. Prior to joining SomaLogic, Nebojsa was the CSO at Replidyne, Inc., a biotechnology company focusing on the development of new small-molecule antibacterial agents. Prior to Replidyne, he was senior director of drug discovery at NeXstar Pharmaceuticals. At NeXstar, he was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class FDA-approved treatment for macular degeneration and Innovative Pharmaceutical Product of the Year in 2005. Nebojsa is also an inventor of Fovista™, an aptamer-based antagonist of PDGF-B currently in late-stage clinical trials for use in combination with VEGF inhibitors in macular degeneration. Nebojsa received his bachelor's degree in molecular biology and Ph.D. in physical organic chemistry from the University of Washington in Seattle and completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.
Nicholas A. Saccomano, Ph.D, Chief Technology Officer
Nick Saccomano joined SomaLogic in 2009 as Chief Technology Officer, a role that includes overseeing the development and applications of the SOMAscan™ proteomic assay. Nick obtained his Ph.D. in chemistry from Columbia University in 1984 under the direction of Professor Gilbert Stork. In 1984, he joined Pfizer Inc. as a research scientist in the CNS discovery group. Between 1985 and 1998, he held several positions in this group, including head of medicinal chemistry. During this time, Nick worked on or led many programs targeting psychiatric and neurological indications including depression, anxiety, psychosis, sleep, stroke, Parkinson's disease, and Alzheimer's disease. In 1998, he was promoted to vice president of discovery technology. In this role, Nick managed and developed a diverse set of enabling technologies used broadly across the drug discovery pipeline. In 2004, Nick was promoted to senior vice president of global research technology and strategic alliances. In 2008, he moved to Bend Research Inc. as chief scientific officer, and he remains a member of the Board of Directors of this organization.
Steven H. Morrissett, J.D., Chief Legal Counsel
Steve Morrissett joined SomaLogic in December 2011 as chief legal counsel. Prior to joining SomaLogic, Steve was a partner at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where he concentrated on intellectual property litigation. He has litigated patent, trademark, trade secret, and antitrust cases, advising clients on litigation strategies, contract negotiations, and other technology-related legal matters. His litigations have included electronic, computer, and medical device technologies. Steve has handled all phases of trials and appeals before state and federal courts and has taken many cases to jury or bench trials. He has more than 15 years of experience in managing complex technology-related litigations.
Before joining Finnegan, Steve served as a trial attorney with a business litigation firm in oil and gas, real estate, and business litigations. Steve also gained extensive jury trial experience as a district attorney, supervising a criminal prosecution office, presenting cases to grand juries, and trying major felonies. He obtained additional experience as a trial attorney in civil and criminal cases and supervising attorney with the Utah Attorney General. During his public service, Steve assisted in preparing state and federal legislation and testified before state legislative committees on issues including computer crimes and Internet jurisdiction.
Steve received his bachelor's in physics from Pomona College, and his J.D. from Hastings College of Law, University of California.
Edward N. Brody, M.D., CMO Emeritus
Ed Brody served as SomaLogic's chief medical officer from 2000 until June 2009. Before SomaLogic, Ed was an advisor to NeXstar Pharmaceuticals, Inc., from 1991 to 1998. In 1998, he joined NeXstar full time as the vice president of drug discovery. From 1988 until January 1999, Ed worked for the Centre de Genetique Moleculaire in Gif-sur-Yvette, France, serving as research director, where he oversaw more than 300 scientists. He has also been an adjunct professor at the University of Colorado since 1996. He is a member of the European Molecular Biology Organization. Ed earned both his M.D. and a Ph.D. in Biochemistry from the University of Chicago.
Mark Messenbaugh, J.D., Executive Director for Corporate Strategy & Development
Mark Messenbaugh serves as SomaLogic's executive director for corporate strategy & development, where he is responsible for developing and structuring key business opportunities and third-party collaborations. Mark joined SomaLogic in 2008. Prior to that, he served as lead director for government relations for the Boys & Girls Clubs of America, where he led strategic initiatives funded by federal, state, and local governments, after starting a partnership between the organization and the office of then-Colorado Attorney General Ken Salazar. In a career spanning business strategy, law, politics, and nonprofit development, Mark has practiced corporate transactional law with the national law firms Arnold & Porter and Davis Polk & Wardwell, led business strategy war games for pharma, served as issues director for Al Gore's Presidential Campaign in 2000, helped write land-use legislation for the Colorado State Senate, and clerked for the U.S. Second Circuit Court of Appeals in New York. Mark earned a bachelor's degree in social studies from Harvard College, studied philosophy on a Fulbright Scholarship to Germany, and received his J.D. from Columbia Law School.
Fintan R. Steele, Ph.D., Executive Director of Communications
Fintan Steele joined SomaLogic in 2011 as executive director for communications. Fintan's background includes more than 20 years of experience in communicating scientific research, particular the science (and its implications) behind the "omics revolution." He was previously director of communications and scientific education at the Broad Institute of MIT and Harvard. Prior to Broad, he was the global head of communications for the Novartis Institutes of BioMedical Research. After completing his doctoral studies in biological science at the University of Notre Dame, Fintan completed post-doctoral studies at the National Institutes of Health and Johns Hopkins School of Medicine.
After leaving active research in 1993, Fintan held several editorial positions for public and private scientific publishers, including "News" and "News & Views" editor for Nature Medicine, executive editor of Genomics, founding executive editor of Molecular Therapy and, most recently, executive editor of Nucleic Acid Therapeutics, the journal of the Oligonucleotide Therapeutics Society. Fintan also holds a M.Div. degree from the St. Meinrad School of Theology and a Masters in medical ethics and religious studies from Indiana University, where he focused on ethical issues in genetic engineering.
Evan King, Executive Director, Business Operations
Evan King joined SomaLogic in 2010 as the director of SomaSciences (the division of SomaLogic that offers services to the life sciences industry). Prior to joining SomaLogic, Evan served as the chief operating officer of CPC Clinical Research for seven years. Before that, he served in positions with progressively more authority and responsibility at several pharmaceutical companies including Gilead Sciences, NeXstar Pharmaceuticals, and Allos Therapeutics, mainly in the areas of regulatory affairs and pharmaceutical project management. Evan graduated from University of California at Santa Barbara with a bachelor's degree in biology.
Jennifer Hargrove, Director, Human Resources
Jennifer Hargrove joined SomaLogic as director of human resources in October of 2012. She has over 20 years of experience in Human Resources, mostly with high technology and biotechnology organizations. Prior to joining SomaLogic, Jennifer was HR Manager at Aircell, a division of Gogo, a telecommunications provider for business aircraft. Her biotechnology experience includes Syntex Labs, Guidant, and Array BioPharma. Her HR experience includes start up pre-public companies and large, well-established public companies. Jennifer has a bachelor's degree in communication from Iowa State University and an MBA from the University of Colorado Denver.